Department of Clinical Biochemistry & Biotechnology, Government College for Women, Nawa-Kadal, Srinagar 190002, India.
Department of Immunology, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan, China.
Int J Biol Macromol. 2024 Nov;281(Pt 1):136020. doi: 10.1016/j.ijbiomac.2024.136020. Epub 2024 Oct 3.
Furin cleavage site (FCS) of the SARS-CoV-2 S protein, which connects the S1/S2 junction, is essential for facilitating fusion with the host cells. Wild-type (Wt) SARS-CoV-2 S protein, PDB ID: 6yvb, lacks a sequence of amino acid residues, including the FCS that links the S1/S2 junction. For the first time, we demonstrated that a stretch of 14 amino acid residues (677QTNSPRRARSVASQ689) forms an antiparallel β-sheet comprising of PRRAR sequence in the FCS within a short loop. Upon comparing the loop content of the S1/S2 junction with that of Wt SARS-CoV-2 containing PRRAR in the FCS, we observed a decrease in antiparallel β-sheet content and an increase in loop content in the B.1.1.7 variant with HRRAR in the FCS. This short loop within antiparallel β-sheet can serve as a docking site for various proteases, including TMPRSS2 and α1AT. We performed a 300-ns simulation of the SARS-CoV-2 receptor binding domain (RBD) using several antibacterial and antiviral ligands commonly used to treat various infections. Our findings indicate that the receptor binding domain (RBD) comprising the receptor binding motif (RBM) utilizes β6 and a significant portion of the loop to bind with ligands, suggesting its potential for treating SARS-CoV-2 infections.
SARS-CoV-2 S 蛋白的弗林裂解位点(FCS)连接 S1/S2 连接处,对于促进与宿主细胞融合至关重要。野生型(WT)SARS-CoV-2 S 蛋白,PDB ID:6yvb,缺乏一段氨基酸残基序列,包括连接 S1/S2 连接处的 FCS。我们首次证明,在 FCS 内的短环中,由 14 个氨基酸残基(677QTNSPRRARSVASQ689)形成的伸展结构形成一个反平行β-片层,包含 FCS 内的 PRRAR 序列。在比较 S1/S2 连接处的环含量与 WT SARS-CoV-2 中 FCS 内 PRRAR 的环含量时,我们观察到 FCS 中含有 HRRAR 的 B.1.1.7 变体中的反平行β-片层含量降低,环含量增加。该反平行β-片层内的短环可以作为各种蛋白酶(包括 TMPRSS2 和α1AT)的对接位点。我们使用几种常用于治疗各种感染的抗菌和抗病毒配体对 SARS-CoV-2 受体结合域(RBD)进行了 300-ns 模拟。我们的研究结果表明,包含受体结合基序(RBM)的受体结合域(RBD)利用β6 和环的很大一部分与配体结合,表明其具有治疗 SARS-CoV-2 感染的潜力。